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Abstract: Background: Delayed cerebral vasospasm (DCVS) due to aneurysmal subarachnoid
hemorrhage (aSAH) and its sequela, delayed cerebral ischemia (DCI), are associated with poor
functional outcome. Endothelin-1 (ET-1) is known to play a major role in mediating cerebral
vasoconstriction. Angiotensin-II-type-1-receptor antagonists such as Sartans may have a beneficial
effect after aSAH by reducing DCVS due to crosstalk with the endothelin system. In this review,
we discuss the role of Sartans in the treatment of stroke and their potential impact in aSAH. Methods:
We conducted a literature research of the MEDLINE PubMed database in accordance with PRISMA
criteria on articles published between 1980 to 2019 reviewing: “Sartans AND ischemic stroke”.
Of 227 studies, 64 preclinical and 19 clinical trials fulfilled the eligibility criteria. Results: There was
a positive effect of Sartans on ischemic stroke in both preclinical and clinical settings (attenuating
ischemic brain damage, reducing cerebral inflammation and infarct size, increasing cerebral blood
flow). In addition, Sartans reduced DCVS after aSAH in animal models by diminishing the effect of
ET-1 mediated vasoconstriction (including cerebral inflammation and cerebral epileptogenic activity
reduction, cerebral blood flow autoregulation restoration as well as pressure-dependent cerebral
vasoconstriction). Conclusion: Thus, Sartans might play a key role in the treatment of patients
with aSAH.
Keywords: aneurysmal subarachnoid hemorrhage; delayed cerebral vasospasm; ischemic stroke;
Sartans; therapeutic interventions
1. Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) induces delayed cerebral vasospasm (DCVS) [1],
cerebral inflammation [2,3], early brain injury [4], cortical spreading depression [5], delayed cerebral
ischemia (DCI) [6], and lack of cerebral autoregulation [7] contributing to poor functional patients’
outcome. DCVS remains a major cause of patient’s morbidity and mortality by inducing delayed
cerebral ischemia [8].
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Multiple studies showed that endothelin-1 (ET-1), a most potent vasoconstrictor [9–11], plays a
key role in the development of DCVS [12–19]. Although endothelin-A-receptor (ETA-R) antagonists in
the treatment of DCVS in animal models are effective [10,20], clinical studies did not show beneficial
effects [21,22]. It has been reported that the polypeptide angiotensin-II acts through two specific
receptors, in essence the angiotensin-II-type-1- and angiotensin-II-type-2-receptor (AT2-1-R and
AT2-2-R). Important to note is that activation of the AT2-1-R results in vasoconstriction while binding
of angiotensin-II to the AT2-2-R causes vasorelaxation [23]. In line with this notion, preclinical as well
as clinical trials showed promising results of Sartans, which are AT2-1-R antagonists, in ischemic stroke.
Hence, Sartans may have a positive effect after aSAH by reducing DCVS due to crosstalk with the
endothelin system. Thus, we aimed to analyze the potential role of Sartans in the treatment of aSAH.
2. Materials and Methods
We conducted a systematic literature research of the MEDLINE PubMed database in accordance
with PRISMA guidelines on preclinical studies on the one and on clinical studies on the other hand
published between 1980 to 2019 reviewing: “Sartans and ischemic stroke” [24]. Only articles in English
were chosen for review. Search items with “Sartans” (n = 19,064) and “ischemic stroke” (n = 89,465)
were extracted. For “Sartans AND ischemic stroke”, 227 publications met the inclusion criteria by
excluding studies with commentary only, any duplicates, or results not commenting on cerebral
effects of Sartans.
Two hundred and twenty-seven studies were assessed for eligibility, 83 met inclusion criteria
for systematic review and qualitative analysis with 64 preclinical studies (Figure 1 demonstrates the
inclusion pathway for basic research studies selected via MEDLINE PubMed search) and 19 clinical
studies (Figure 2 shows the inclusion pathway for clinical research studies selected via MEDLINE
PubMed search).Brain Sci. 2020, 10, x FOR PEER REVIEW 3 of 23 
    
Figure 1. Two hundred and twenty-seven articles (published 01-01-1980–01-07-2019) were detected 
for preclinical and clinical research articles. After manual abstract screening for preclinical research 
articles only, 79 articles remained for further analysis. Each of the 79 articles was explicitly screened 
for potential drug applications after ischemic stroke. Finally, 64 articles were included for qualitative 
analysis. 
Figure 1. Two h ndred and twenty-seven articles (publis d 01-01-1980–01-07-2019) w re detected for
preclinical and clinical research articles. After manual abstract screening for preclinical research articles
only, 79 articles remained for further analysis. Each of the 79 articles was explicitly screened for potential
drug applications after ischemic stroke. Finally, 64 articles were included for qualitative analysis.
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Figure 2. Two hundred and twenty-seven articles (published 01-01-1980–01-07-2019) were detected 
for preclinical and clinical research articles. After manual abstract screening for clinical research 
articles only, 46 articles remained for further analysis. Each of the 46 articles was explicitly screened 
for potential drug applications after ischemic stroke. Finally, 19 articles were included for final 
analysis. 
3. Results 
3.1. Preclinical Studies on Sartans in Animal Models of Ischemic Stroke 
The search finally yielded 64 preclinical studies on “Sartans AND ischemic stroke”, eligible for 
systematic review (Table 1). 
Figure 2. Two hundred and twenty-seven articles (published 01-01-1980–01-07-2019) were detected for
preclinical and clinical research articles. After manual abstract screening for clinical research articles
only, 46 articles remained for further analysis. Each of the 46 articles was explicitly screened for
potential drug applications after ischemic stroke. Finally, 19 articles were included for final analysis.
Of the articles included in the final analysis, a systematic review on the beneficial and non-beneficial
effect in the preclinical and clinical settings was performed. Summary measures are reported as
outcome measures (i.e., infarct size, neurocognition, inflammation).
3. Results
3.1. Preclini al Studies on Sartans in Animal Models of Ischemic Stroke
The search finally yielded 64 preclinical studies on “Sartans AND ischemic stroke”, eligible for
systematic review (Table 1).
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Table 1. Tabular listing of different preclinical studies showing various effects of Sartan administration (Abbreviations: Angiotensin-II-type-1-receptor (AT2-1-R);
Angiotensin-II-type-2-receptor (AT2-2-R); common carotid artery occlusion (CCAO); chemokine receptor 2 (CCR2); cluster of differentiation (CD); candesartan (CS);
desoxy ribonucleic acid (DNA); endothelial nitric oxide synthase (eNOS); endothelin-A-receptor (ETA-R); hours (h); inducible nitric oxide synthase (iNOS); irbesartan
(IS); kilogram (kg); losartan (LS); middle cerebral artery occlusion (MCAO); matrix-metallo-proteinase (MMP); messenger ribonucleic acid (mRNA); milligram (mg);
minutes (min); n-acetyl-glucosamine oligomer (NAGO); nlr family pyrin domain containing 3 (NLRP3); oxygen glucose deprivation (OGD); olmesartan (OMS);
stroke-resistant spontaneously hypertensive rats (SR-SHR); telmisartan (TMS); tumor necrosis factor alpha (TNFα); ribonucleic acid (RNA); vascular endothelial
growth factor (VEGF); valsartan (VS)).
Drug Model Outcome Beneficial Effect Special Remarks
TMS [25] Global ischemic mice model Cerebral perfusion Restored cerebral blood flow -
TMS [26] MCAO mice Neuroscore, infarct size
Improved neuroscore and decreased infarct size,
increased cerebral blood flow, reduced superoxide
production and inflammatory cytokine expression
-
TMS [27]
Murine model of
transient and permanent
focal ischemia
Infarct size,
reperfusion injury
Reduced stroke volume 72 h after transient ischemia,
likewise pro-inflammatory adhesion molecules and
infiltration of inflammatory cells in the ischemic region
No reduction in stroke volume 72 h
after permanent ischemia
TMS [28] MCAO mice Focal brain ischemia,atherosclerotic lesions
Attenuated ischemic brain damage, neurological
deficits and superoxide production in ischemic area;
attenuated reduction of cerebral blood flow in the
penumbra without significantly changing
blood pressure
Anti-atherosclerotic effects
TMS [29] MCAO rat Cerebral perfusion
Improved cerebral blood flow, enhanced vascular
density (CD31 immunofluorescence staining),
antiapoptotic effects
-
TMS [30] MCAO rat
Cognitive function,
level of matrix
metalloproteinases
Improved spatial memory ability, decreased
expression levels of MMP-2 and MMP-9 -
TMS [31] MCAO rat
Behavior alterations,
neuroprotective effects
on secondary
reperfusion phase
Normalized behavioral alterations comparable to
pre-ischemic treatment (protected neurons from
ischemic reperfusion injury), attenuated excitatory
amino acid release in secondary reperfusion phase
In combination with nimodipine.
Drug treatments immediately after
reperfusion, effects compared
with pretreatment
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Table 1. Cont.
Drug Model Outcome Beneficial Effect Special Remarks
TMS [32] MCAO rat
Effects on neurovascular
unit and
neuroinflammation
Reduced decrease of NAGO-positive endothelium,
similar increase of MMP-9 positive neurons and
NLRP3-positive inflammasome in the cerebral cortex
Low dose TMS improved changes
without lowering blood pressure,
high dose TMS further improved
changes with lowering
blood pressure
TMS [33] Open skull preparation rat
Cerebral arteriolar
pressure, cerebral blood
flow, internal
vessel diameter
Normalization of arteriolar pressure and lower limit
of cerebral autoregulation Combined with Ramipril
TMS [34] MCAO rats Metabolic relatedpost-ischemic changes Ameliorated metabolic related post-ischemic changes -
TMS [35] MCAO rats
Neurological outcome,
infarct volume,
inflammation
Improved outcome, reduced infarct volume
and inflammation
Subcutaneous TMS application 5
days prior to MCAO
with reperfusion
TMS [36] MCAO rats
Infarct volume,
immunohistochemical
parameters
Significantly reduced infarct volume, reduced
neurotoxic cytosolic phospholipase A2, ameliorates
ischemic changes of neurons in the peri-infarct area
Pretreatment for 7 days
TMS [37]
Collagenase infusion or
autologous blood injection
to induce intracerebral
hemorrhage in rats
Hemorrhage volume,
functional recovery
Reduced hemorrhage volume, brain edema,
inflammatory/apoptotic cells in perihematomal area;
induced endothelial nitric-oxide-synthase, decreased
oxidative stress, apoptotic signals, and TNFα
-
TMS [38]
Stroke-resistant
spontaneously
hypertensive rats
Oxidative stress
Reduced advanced glycation end product,
4-hydroxy-2-nonenal- and phosphorylated
a-synuclein-positive cells in the cerebral cortex
and hippocampus
-
CS [39] MCAO mice Ischemic brain damage
Reduced ischemic brain area and neurological deficits
in non-hypotensive doses; improved reduction of
brain surface blood flow and inhibited superoxide
production in the cortex and brain arterial wall at
non-hypotensive and hypotensive doses; AT2-2-R
expression in the ischemic area was increased by prior
pretreatment with CS
-
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Table 1. Cont.
Drug Model Outcome Beneficial Effect Special Remarks
CS [40] MCAO mice Antioxidant enzymeactivity
Restored superoxide dismutase activity and cerebral
blood flow -
CS [41] MCAO rats
Neurobehavioral
outcome, infarct size,
vascular density
Improved neurobehavioral outcome, reduced infarct
size and vascular density
In vitro vascular density was
assessed using human brain
endothelial cells
CS [42] MCAO rats Infarct size,neurological outcome
Improved neurobehavioral and motor functions,
decreased infarct size Intravenous CS administration
CS [43] MCAO rats Neurological outcome Improved recovery from ischemic stroke Only 0.3 mg/kg CS withneuroprotective function
CS [44] MCAO rats Neurological outcome,oxidative enzymes
Improved motor function and reduced endoplasmatic
reticulum stress markers Only early beneficial effect after 24 h
CS [45] MCAO rats
Neurological outcome,
vascular
density/synaptogenesis
Improved functional outcome, increased vascular
density/synaptogenesis only in the control group
Intracerebroventricular injection of
short hairpin RNA lentiviral
particles to knock down
brain-derived neurotrophic factor
or nontargeting control vector
CS [46] MCAO rats Angiogenesis
Induced prolonged proangiogenic effect and
upregulation of VEGF-A and VEGF-B;
stabilized hypoxia-inducible factor-1a and
preserves angiopoetin-1
-
CS [47] Spontaneouslyhypertensive rats Angiogenesis
Exerted proangiogenic effects on brain microvascular
endothelial cells -
CS [48]
In vitro monolayer model
using rat brain capillary
endothelial cells
Stability of blood
brain barrier
Improved cell function and viability of brain capillary
endothelial cells under OGD Normoxia versus 6 h OGD
CS [49] MCAO rats Neurological outcome,infarct size
Improved neurological function, significantly reduced
blood brain barrier disruption/edema/infarct volume -
CS [50] MCAO rats Infarct size, functionalrecovery, neuroplasticity
Significantly reduced infarct size, ameliorated
functional recovery and increased
neuroplasticity markers
-
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Table 1. Cont.
Drug Model Outcome Beneficial Effect Special Remarks
CS [51] MCAO rats Infarct size,neurological outcome
Decreased infarct size and improved
neurological outcome -
CS [52] MCAO rats Mortality, infarct size Significantly reduced mortality and infarct size -
CS [53] MCAO rats Infarct size Reduced infarct size Oral administration
CS [54] MCAO rats Infarct size, edema,neurological outcome
Reduced infarct size, edema formation and improves
neurological outcome -
CS [55] MCAO rats Infarct size,neurological outcome
Significantly reduced stroke volume and improved
neurological outcome -
CS [56] MCAO rats Infarct size, edema Reduced infarct size and edema, improvedneurologic function -
CS [57] MCAO rats Infarct volume,neurological deficit
Reduced infarct size and improved
neurologic outcome -
CS [58] MCAO rats Infarct volume,neurological deficits
Reduced infarct size, improved neurological outcome,
reduced lipid peroxidation Subcutaneous infusion for 14 days
CS [59] MCAO rats Infarct volume,neurological deficits
Reduced infarct size/edema and improved
neurological outcome
Long-term blockade (subcutaneous
injection twice daily 5 days before
ischemia), not short-term
administration (intravenous once
4 h prior to ischemia), improves
neurological outcome
CS [60] MCAO rats Infarct volume,brain edema
Significantly reduced cortical infarct volume and
brain edema -
CS [61] Bilateral CCAO rats Neurological outcome,oxidative damage
Attenuated neurobehavioral alterations, oxidative
damage and restored mitochondrial
enzyme dysfunction
Occlusion for 30 min, followed by
24 h reperfusion; CS pretreatment
for 7 days
CS [62] MCAO rats Infarct size Reduced infarct area -
CS [63] MCAO rats Infarct size,neurological outcome
Pretreatment reduced infarct area and improved
neurological outcome -
CS [64] MCAO rats Infarct size,neurological outcome
Reduced infarct size and neurological deficits;
significantly reduced mRNA expression of
inflammatory markers
-
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Table 1. Cont.
Drug Model Outcome Beneficial Effect Special Remarks
CS [65] Spontaneouslyhypertensive rats AT2-1-R expression
Increased AT2-2-R expression in spontaneously
hypertensive rats
CS application via subcutaneous
osmotic minipumps for 4 weeks
CS [66] MCAO rats Neurological outcome,vascular density
Improved neurological outcome and increased
vascular density -
CS [67] Embolic stroke model Mortality, neurologicaloutcome, infarct size
Significantly decreased mortality, neurological deficits,
and infarct size Injection of calibrated microspheres
CS [68] MCAO rat Infarct size,neurological outcome
Reduced infarct size and improved
neurological outcome
Combined treatment with
ETA-R antagonist
CS [69] MCAO rats Contractile response toangiontensin II Abolished the enhanced responses to angiotensin II -
CS [70] MCAO rats Infarct volume,neurological outcome
Reduced infarct size with low but not high dose of CS,
improved neurological outcome Subcutaneous CS administration
CS [71] MCAO rats Infarct size, neuroscores,cerebral blood flow Reduced infarct size and increased cerebral blood flow Intravenous CS administration
CS [72] Spontaneouslyhypertensive rats
Vascular remodeling,
expression
of eNOS/iNOS
Reversed negative vascular remodeling and
alterations in eNOS/iNOS expression -
OMS [73] Bilateral CCAO mice Cognitive impairment Ameliorated cognitive impairment -
OMS [74] Single carotid ligation strokemodel gerbil Survival Significantly increased survival at day 30 -
OMS [75] MCAO rats Neurological outcome,infarct size, cell death
Significantly improved functional scores, reduced
infarct size and cell death
Only continuous administration of
OMS before and after stroke
reduced oxidative stress levels
OMS [76] MCAO rats Infarct volume Reduced infarct volume 48 h after transient focalbrain ischemia
OMS administration via
drinking water
OMS [77] MCAO rats
Stroke index score,
infarct volume,
quantity of MMPs
Improved stroke index score, infarct volume,
reduced cerebral edema and upregulation of MMPs -
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Table 1. Cont.
Drug Model Outcome Beneficial Effect Special Remarks
VS [78] MCAO mice
Infarct volume,
DNA damage,
superoxide production
Significantly reduced infarct size, DNA damage,
superoxide production, mRNA levels of monocyte
chemoattractant protein-1, increases cerebral blood
flow, increased eNOS activation and nitric
oxide production
-
VS [79] MCAO mice Infarct volume,neurological outcome
Significantly reduced infarct volume and improved
neurological outcome -
VS [80] MCAO mice Infarct volume,neurological outcome
Significantly reduced ischemic area, neurological
deficits, reduction of cerebral blood flow and
superoxide production
-
VS [81] High salt loaded SR-SHR Brain injury Enhanced protective effects against brain injury, whitematter lesions and glial activation Combined with amlodipine
IS [82] MCAO rats Infarct size,neurological outcome
Reduced infarct size and number of apoptotic cells in
the peri-infarct cortex on day 3, attenuated invasion of
microglia and macrophages on day 3 and
7 after ischemia
-
IS [83] MCAO rats Neurological outcome Significantly improved neurological outcome
Administration of IS
intracerebroventricularly
over 5 days
IS [84] MCAO rats Infarct size Reduced infarct volume
Coadministration of
propagermanium
(CCR2 antagonist)
LS [85] Single carotid ligation strokemodel gerbil Mortality
Did not increase mortality after unilateral carotid
ligation in gerbils -
LS [86] MCAO mice OGD-induced cell injury
Abolished OGD-induced exaggeration of cell injury in
mice overexpressing renin and
angiotensinogen animals
-
LS [87] MCAO rats Gene expression levelsof pro-apoptotic genes
Significant reduced gene expression of
pro-apoptotic genes -
LS [88]
Cerebral focal ischemia by
cauterization of cortical
surface vessels rats
Cessation of blood flow,
infarct size
Maintained angiogenesis, vascular delivery,
and significantly decreased infarct size
Administration of LS in drinking
water 2 weeks before
inducing ischemia
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Telmisartan (TMS), a selective AT2-1-R antagonist, displayed the capacity to increase cerebral
blood flow (CBF) in global cerebral ischemia [25]. It ameliorated reduction of CBF in the penumbra
(0.3 mg/kg/day) without significant changes in blood pressure (BP) [28]. Following middle cerebral
artery occlusion (MCAO), TMS decreased ischemic infarct area, reduced superoxide production
and expression of inflammatory cytokines, infiltration of inflammatory cells, improved neurological
scores, and increased CBF [26,27]. Angiogenesis in ischemic areas after MCAO was enhanced by
TMS, as well as neuroregeneration by downregulating caspase activation [29]. A combination of
TMS with nimodipine (2.5–5 mg/kg) in a transient MCAO rat model revealed beneficial influences
affecting the attenuation of excitatory amino acids in different brain regions nine days after MCAO
with neurobehavioural outcomes normalized seven days after MCAO [31]. Low doses of TMS
(0.3–3 mg/kg/d) after MCAO in a model of stroke-resistant spontaneously hypertensive rats (SR-SHR)
reduced progressive decrease of N-acetylglucosamine oligomer and increase of MMP-9 positive
neurons without reducing BP [32]. Likewise combination therapies with ramipril (0.8 mg/kg per day
TMS + 0.1 mg/kg per day ramipril or 0.5 mg/kg per day TMS + 0.25 mg/kg per day ramipril) normalized
BP as well as maintained cerebral blood flow autoregulation [33]. Deguchi et al. demonstrated that
TMS dose-dependently (0.3 mg/kg/day or 3 mg/kg/day) ameliorated metabolic syndrome related
changes in the post stroke brain of SR-SHR with direct neuroprotective effects [34]. Moreover, incidence
of stroke was reduced along with prolonged survival and improved neurological outcome following
TMS application (0.5 mg/kg once daily) [35]. Pretreatment of rats with TMS (1 mg/kg) seven days
before inducing cerebral ischemia also showed significant reduced infarct size and histopathologically
normal appearance of neurons in the periinfarct cortical regions [36].
Candesartan (CS), another AT2-1-R antagonist, reduced ischemic brain damage following MCAO
occlusion [39]. CS and curcumin together significantly restored superoxide dismutase activity and
blood flow compared with the untreated group [40]. Further, CS upregulated vascular endothelial
growth factor (VEGF) B after induction of focal cerebral ischemia using a MCAO model. In contrast
to saline-treatment after reperfusion, CS further improved neurobehavioral and motor functions
and decreased infarct size [41]. VEGF-B silencing was shown to diminish CS (1 mg/kg) protective
effects [42]. CS (0.3 mg/kg) was able to improve recovery from ischemic stroke in low doses by
maintaining blood pressure during reperfusion [43]. CS induced early protective effects with
improvement in motor function, upregulated brain-derived neutrotrophic factor (BDNF), and also
reduced endoplasmatic reticulum stress markers [44]. In a MCAO BDNF, knock-out model rats received
CS or saline at reperfusion for 14 days, revealing better functional outcomes, increased vascular density,
and synaptogenesis in the CS (1 mg/kg) group [45,46]. In addition, CS (0.16 µM) significantly increased
BDNF production [47]. Furthermore, CS (10 nM) improved cell function and viability of brain
capillary endothelial cells under oxygen glucose deprivation, providing protective blood–brain-barrier
(BBB) effects [48]. In other transient MCAO rat models, CS (0.1 mg/kg; 0.3 mg/kg; 1.5 or 10 mg/kg
per day; 0.1, 1 and 10 mg/kg; 0.1, 0.3 or 1 mg/kg; 0.1 mg/kg twice daily; 1 mg/kg; 0.3 or 3 mg/kg
per day; 0.5 mg/kg per day for 14 days; 0.1 or 0.3 mg/kg; 0.5 mg/kg per day for 3 to 14 days) showed
improved neurological function with significant reduction in BBB disruption, in cerebral ischemia,
and in edema [39,49–60]. In a bilateral common carotid artery occlusion (CCAO) model in rats,
pretreatment with CS (0.1 and 0.3 mg/kg) and atorvastatin significantly attenuated neurobehavioral
alterations, oxidative damage, and restored mitochondrial enzyme dysfunction compared to the control
group [61,62]. AT2-1-R administration prior to ET-1 induced MCAO provides neuroprotective effects,
with CS (0.2 mg/kg per day for seven days) pretreatment attenuating infarct size and neurological
deficits without altering systemic BP [63]. Pretreatment with CS for five days significantly decreased
mortality, neurological deficits, and infarct size [67]. A combined inhibition of AT2-1- (0.05 mg/kg per
day) and ETA-receptors decreased brain damage as well; additionally, an upregulation of AT2-1-R in
ischemic middle cerebral artery smooth muscle cells (SMCs) was found [68,69]. Also, early (3 h) and
delayed (24 h) effects of CS treatment (0.3 and 3 mg/kg) continued for seven days after onset of MCAO
with reperfusion in normotensive rats involved a reduction of the infarct volume by low doses of CS [70].
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CBF in CS (0.5 mg/kg) pretreated animals at 0.5 h after MCAO was significantly increased compared to
the control group [71]. Other groups additionally showed a four-week CS-pretreatment (0.3 mg/kg
per day) before MCAO clearly associated with complete reversal of a decreased lumen diameter and
increased media thickness as well as decreased endothelial nitric oxide synthase (eNOS) and increased
inducible nitric oxide synthase (iNOS) protein and mRNA in SR-SHR and in a normotensive control
group [72].
Olmesartan (OMS), an AT2-1-R antagonist, has been evaluated in a bilateral CCAO model in mice,
revealing improved cognitive outcome, neuroprotective effects, attenuation of oxidative hippocampal
stress, and suppression of BBB disruption compared to control groups [73]. A single carotid ligation
stroke model in gerbils showed that OMS (10 mg/kg per day started 36 h after stroke) was associated
with an increased survival [74]. Other studies demonstrated that OMS (10 mg/kg per day for 14 days
after infarct; 10 mg/kg per day for 7 days before and 14 days after infarct; 10 mg/kg per day for 7 days
before infarct) treatment in a rat MCAO model showed significantly better functional scores and
reduced infarct size and cell death [75]. OMS (0.01 or 0.1 µmol/kg per hour for seven days) reduced
brain angiotensin II, MMP-2 and MMP-9 upregulation following brain ischemia [77].
Valsartan (VS), a selective AT2-1-R antagonist, reduced ischemic brain area and improved the
neurological deficit after MCAO with restoration of cerebral blood flow [78]. VS significantly reduced
infarct volume and improved the neurological deficit scores. VS at nonhypotensive doses significantly
diminished ischemic area, neurological deficits, and reduction of cerebral blood flow as well as
superoxide production [27,78,80].
Irbesartan (IS), a selective AT2-1-R antagonist improved motor functions, reduced infarct size and
decreased the number of apoptotic cells particularly in the periinfarct area by attenuated invasion of
activated microglia likewise macrophages [82–84].
Losartan (LS), a clinical established selective AT2-1-R antagonist, did not increase mortality in
acute cerebral ischemia [85]. Also, LS (20 µmol/L) abolished ischemic exaggeration of cell injury [26,86].
Expression levels of pro-apoptotic genes were significant reduced by LS treatment [87]. Further LS
administration initiates cerebral angiogenic response with a significantly larger vessel surface area,
and administration before initiation of cerebral focal ischemia (50 mg/day for 2 weeks) markedly
reduces infarct size [88].
3.2. Clinical Studies on Sartans in Ischemic Stroke
The search yielded 19 clinical studies on “Sartans AND ischemic stroke”, eligible for systematic
review (Table 2). Beneficial aspects of using AT2-1-R antagonists before the onset of ischemic stroke
have already been elucidated in a retrospective analysis of 151 patients [89].
Table 2. Tabular listing of different clinical studies showing various effects of Sartan administration
(Abbreviations: Candesartan (CS); hours (h); losartan (LS); milligram (mg); minutes (min); µmol
(micromolar); modified ranking Scale (mRS); mol (molar); nmol (nanomolar); telmisartan (TMS);
valsartan (VS)).
Drug Outcome Beneficial Effect Special Remarks
CS [90]
Vascular event (vascular death,
nonfatal stroke or nonfatal myocardial
infarction) over 6 months and mRS
No overall effect on vascular events in
ischemic and/or hemorrhagic stroke,
adjusted odds ratio for vascular events of
patients treated within 6 h
reached significance
Administration at least within 30 h of
ischemic or hemorrhagic stroke. CS
treatment for 7 days, increasing from
4 mg on day 1 to 16 mg on day 3 to 7
CS [91] Barthel index and level of careassessed after 6 months
No significant effects on Barthel Index or
level of care at 6 months
Administration at least within 30 h of
ischemic or hemorrhagic stroke. CS
treatment for 7 days, increasing from
4 mg on day 1 to 16 mg on day 3 to 7
CS [92]
Vascular death, myocardial infarction,
stroke during first 6 months and
functional outcome at 6 months
Significant trend towards a better effect of
CS in patients with larger infarcts; no
differences in treatment effect for composite
vascular end point
CS treatment for 7 days, increasing
from 4 mg on day 1 to 16 mg
on day 3 to 7
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Table 2. Cont.
Drug Outcome Beneficial Effect Special Remarks
CS [93]
Vascular death, myocardial infarction,
stroke during first 6 months and
functional outcome at 6 months
After 6 months the risk of the composite
vascular endpoint did not differ between
treatment groups
CS treatment for 7 days, increasing
from 4 mg on day 1 to 16 mg
on day 3 to 7
CS [94]
Safety of modest blood pressure
reduction by CS cilexetil in the early
treatment of stroke
The cumulative 12 months mortality and
the number of vascular events differed
significantly in favor of the
CS cilexetil group
CS treatment with 4 mg on day 1;
dosage increased to 8 mg on day 2 or
16 mg if blood pressure exceeded
160 mmHg systolic or
100 mmHg diastolic
CS [95]
Short-term safety of blood pressure
reduction in hypertensive patients
with acute ischemic stroke
CS treatment safely reduces blood pressure
in hypertensive patients with acute
ischemic stroke
4 mg/day for 14 days
CS [96]
Adhesion of neutrophils to human
endothelial cells in acute
ischemic stroke
CS inhibited the adhesion of neutrophils to
vascular endothelium in ischemic stroke
patients (not in chronic stroke patients or
healthy volunteers)
Incubation with 10−9 mol for 30 min
CS [97]
Effect of blood pressure lowering in
patients with acute ischemic stroke
and carotid artery stenosis (Vascular
death, stroke, myocardial infarction,
and functional outcome at 6 months)
No evidence that CS effect is qualitatively
different in patients with carotid
artery stenosis
CS treatment for 7 days, increasing
from 4 mg on day 1 to 16 mg
on day 3 to 7
VS [98]
Safety of modest blood pressure
reduction within 48 h of acute
ischemic stroke
After 90 days the mRS as well the rate of
major vascular events differed not
significantly between both groups
80 mg/day (dose was modified in the
subsequent six-days of treatment if
the target systolic blood pressure was
not achieved)
VS [99] Effect of vs. on humanplatelet aggregation
VS exhibited significant inhibition of
human platelets and therefore might be
able to reduce vascular ischemic events
10 nmol to 100 µmol
TMS [100] Time to first recurrent stroke
Low glomerular filtration rate (<60
mL/min) is independently associated with a
higher risk of recurrent stroke, TMS not
able to mitigate this risk
TMS dosage not reported
TMS [101] Recurrent stroke of any type
Similar rates of recurrent strokes comparing
aspirin plus extended-release dipyridamole
with clopidogrel and TMS
80 mg/day
TMS [102] Prevention of cerebral whitematter lesions
TMS on top of existing antihypertensive
medication did not prevent the progression
of white matter lesions
80 mg/day. Analysis limited by the
relatively short follow-up
TMS [103]
Functional outcome at 30 days
(primary outcome), death, recurrence,
and hemodynamic measures up to
90 days (secondary outcomes)
TMS treatment appears to be safe with no
excess in adverse events and not associated
with a significant effect on functional
dependency, death, or stroke recurrence
80 mg/day
TMS [104] Recurrent stroke
TMS initiated soon after ischemic stroke
and continued for 2.5 years did not
significantly lower the rate of recurrent
stroke, major cardiovascular events, or
diabetes
80 mg/day
LS [105] Global change of cerebral blood flow LS treatment increases the global cerebralblood flow despite blood pressure lowering 50–100 mg/day for 4 weeks
LS [106]
Effect on stroke in patients with
isolated systolic hypertension and left
ventricular hypertrophy
Incidence of any stroke (40% risk
reduction), fatal stroke (70% risk reduction),
and atherothrombotic stroke (45% risk
reduction) was significantly lower in the
LS treated group compared to atenolol
treated patients
Mean LS dose of 79 mg
LS [107]
Effect on global and focal cerebral
blood flow in hypertensive patients
2–7 days after stroke
No neurological deterioration in the
LS group 25–50 mg/day
LS [108]
Spontaneous platelet aggregation and
P-selectin levels (in patients with
hypertension and chronic
ischemic stroke)
Spontaneous platelet aggregation was not,
P-selectin levels significantly reduced after
LS treatment. This suggests that standard
doses of LS display antiplatelet effect
50 mg/day
CS has been evaluated in the Scandinavian Candesartan Acute Stroke Trial (SCAST). Within 30 h of
ischemic or hemorrhagic stroke, 2029 patients either received CS- or placebo-treatment. The modified
ranking Scale (mRS) was used for outcome analysis. CS showed no overall effect on vascular events
in ischemic and/or hemorrhagic stroke, and the adjusted odds ratio for vascular events of patients
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treated within 6 h reached significance [90]. At six months, activities of daily living and level of care
were assessed. In more than 1800 patients, over 1500 suffered ischemic and almost 250 hemorrhagic
strokes. No statistically significant effects of CS on Barthel index or level of care could be identified [91].
Furthermore, the SCAST group evaluated whether the effect of CS treatment varies in subtypes of
over 1700 ischemic strokes. Concerning functional outcomes, a trend towards a beneficial effect
of CS was observed in patients with larger infarcts (total anterior circulation or partial anterior
circulation) than in patients with smaller lacunar infarcts [92]. Further on, over 2000 SCAST patients
were randomly allocated to placebo or CS treatment for seven days with increasing doses from 4 mg
(starting day 1) to 16 mg (from day 3 to 7). After six months’ follow-up, the risk of the composite
vascular endpoint did not differ between the placebo and CS treatment group [93]. Also, the Acute
Candesartan Cilexetil Therapy in Stroke Survivors study confirmed that administration of CS in the
acute phase of stroke in 339 patients confers long-term benefits in patients who sustained acute ischemic
stroke [94]. VS has been evaluated in a multicenter trial concerning efficacy and safety of modest
blood pressure reduction within 48 h in more than 370 patients with acute ischemic stroke, considering
the primary outcome death or dependency. The VS-treated group showed 46 of 187 patients with a
90-day mRS of 3–6, compared with 42 of 185 patients in the control group. The rate of major vascular
events did not differ significantly between both groups [98]. TMS has also been evaluated concerning
beneficial effects after stroke treatment. A multicenter trial, involving more than 18,500 patients
with ischemic stroke, had a follow-up of 2.5 years. The primary outcome parameter was time to
first recurrent stroke. Only short-term add-on TMS (80 mg/day) treatment did not mitigate this
risk [100,101]. Treatment with TMS (80 mg/day) did not prevent progression of white matter lesions
in patients with recent ischemic stroke [102]. Another study group enrolled 20,332 patients and
analyzed 1360 patients within 72 h of ischemic stroke onset (TMS vs. placebo) concerning functional
outcome after 30 days as primary outcome. Combined death or dependency did not differ between
the treatment groups, showing treatment with TMS (80 mg/day) in patients with acute mild ischemic
stroke and mildly elevated BP safe with no excess in adverse events [103]. Also, effects of TMS
(80 mg/day) initiation early after stroke have been analyzed. From 20,332 patients with recent ischemic
stroke, 10,146 patients were randomly assigned in the TMS group and 10,186 in the placebo group;
8.7% in the TMS group and 9.2% in the placebo group suffered from subsequent stroke, showing
no significant reduction of recurrent stroke after early initiation [104]. LS has also been analyzed in
recent clinical stroke trials. In a double-blinded multi-center trial, 196 hypertensive patients with
previous ischemic stroke were randomized to cilnidipine- or LS-treatment (50–100 mg per day for
four weeks) once daily for four weeks. Both treatments, however, increased global CBF despite BP
lowering [105]. Additionally, the effect of long-term therapy with LS regarding cognitive function
in 6206 essential hypertonic patients with additional cerebrovascular risk factors was investigated.
The LS-based antihypertensive treatment increased the proportion of patients with normal cognitive
function [109]. Also, the Losartan Intervention for Endpoint reduction in hypertension study group
reported cardioprotective effects of a LS-based antihypertensive regimen. The incidence of any
stroke, fatal stroke, and atherothrombotic stroke was significantly lower in LS-treated compared to
the atenolol-treated isolated systolic hypertensive patients [106]. Other groups assessed the effect
of LS treatment on mean arterial blood pressure, global, and focal CBF in 24 hypertensive patients
without occlusive carotid disease 2–7 days after ischemic stroke and/or transient ischemic attack.
LS (25–50 mg per day) was generally well tolerated and none of the patients suffered neurological
deterioration. No changes occurred in internal carotid artery flow or cortical as well as hemispheric
CBF [107].
3.3. Therapeutic Interventions After aSAH
Poor patients’ outcome after aSAH is owed a multifactorial process (early brain injury, DCVS,
DCI, cerebral inflammation, cortical spreading depression, loss of pressure dependent cerebral
autoregulation) [4,5,7,9,110–113]. DCVS is treated with moderate hypertensive, normovolemic,
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hemodilution, and in cases of therapy-refractory, DCVS with intra-arterial spasmolysis or balloon
dilatation [114,115]. Research to improve poor functional outcome in patients suffering from
aSAH and related DCVS is pivotal [1,5,21,116,117]. Multiple preclinical and clinical trials showed
the effect of ET-1 in mediating DCVS after aSAH. CONSCIOUS-1, a randomized, double-blind,
placebo-controlled study assessed the efficacy of intravenous clazosentan (ETA-R antagonist) in
preventing vasospasm following aSAH. It significantly decreased angiographic DCVS with a trend
for reduction in vasospasm-related morbidity/mortality [118]. CONSCIOUS-2 assigned patients
with aSAH and clip ligation to clazosentan- or placebo. Thereby, clazosentan showed no significant
difference in the mortality and vasospasm-related morbidity [119]. CONSCIOUS-3 assessed whether
clazosentan reduced DCVS-related morbidity and mortality after aSAH and endovascular coiling.
Pulmonary complications and anemia were more common in patients with clazosentan administration
than in the placebo group, and mortality rates after 12 weeks were the same, respectively [120].
The REVERSE-study, infusing clazosentan intravenously in patients developing moderate to severe
angiographic vasospasm after aSAH, showed a clear pharmacodynamic dilating effect on DCVS 24 h
in most patients suffering aSAH, being able to reverse established angiographic vasospasm [22].
Antihypertensive agents are usually discontinued to maintain a sufficient mean arterial cerebral
perfusion pressure considering the prolonged phase of DCVS between days 5 to 14 after the ictus [114].
In contrast, nimodipine, a calcium-channel antagonist, is administered for risk reduction of DCVS,
yet rather its neuroprotective effects have been discussed in its beneficial role in aSAH [8,121].
3.4. Effects of Losartan Following aSAH
LS, an already well-established antihypertensive drug in daily clinical practice and well examined
in preclinical and clinical settings of ischemic stroke, shows promising results by attenuating cerebral
inflammation and restoring cerebral autoregulation [64,105,122–125]. Facing preclinical aSAH research,
beneficial effects of Sartans have been shown. Under already physiological conditions, LS diminished
cerebral inflammation and associated DCVS [126] as well as ET-1 mediated vasoconstriction. Targeted
ETB1- and ETA-R-antagonism under LS administration revealed a direct modulatory ETB1-R dependent
effect via inducing upregulation of the NO-pathway with a significantly increased relaxation
accompanied with enhanced sensitivity of the ETB1-R [23]. After induction of aSAH, ET-1-induced
vasoconstriction was likewise decreased by LS preincubation, abolished after pretreatment with an
ETB1-R antagonist. In precontracted vessels with LS and ETA-R-antagonism, ET-1 induced a higher
vasorelaxation compared to the control group without, clearly demonstrating a modulatory and
functional restoring effect of LS on the normally after aSAH impaired ETB1-R function [127].
Beneficial effects of LS on ET-1- and PGF2α-mediated DCVS after aSAH in a rat model have been
reported, too [23,127]. An ET-1 mediated vasoconstriction was diminished, and ETB1-R mediated
vasorelaxation under selective ETA-R blockade was restored [126,127]. In addition, PGF2α-elicited
vasoconstriction of a basilar artery was markedly diminished [23,126,127]. Interestingly, several
work groups could also verify positive vasomodulating effects of LS on the cerebral vessel wall,
especially affecting SMCs [128,129]. Furthermore, aneurysm rupture was prevented in mice under
LS treatment [129]. As already mentioned, after aSAH, increased synthesis of ET-1 triggers enhanced
cerebral vasoconstriction; loss of the ETB1-R mediated vasorelaxation contributes to this effect, too [127].
Furthermore, upregulated AT2-1-R and PGF2α-synthesis contribute in enhancing and maintaining
cerebral vasocontraction [7,130–133]. LS showed promising aspects in preclinical aSAH studies and
therefore might have an effect in the treatment of patients with aSAH.
4. Discussions
This systematic review demonstrated Sartan administration after ischemic stroke clearly associated
with beneficial effects on preclinical models as well regarding clinical trials. Clear evidence of which
doses in preclinical and clinical settings for treatment of ischemic stroke with Sartans exactly might be
useful are heterogenous and therefore not consistent yet. In a preclinical setting, Sartans significantly
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reduced infarct volume and edema, augmented CBF, diminished superoxide production, inflammatory
processes, and disruption of the BBB. In clinical studies, clear trends towards a better functional outcome
and neurocognitive function after stroke with Sartan use have been reported. Thus, the question arises
whether Sartans might provide positive effects on DCVS or DCI after aSAH. In summary, LS provided
in a preclinical physiological and pathophysiological setup after aSAH beneficial aspects in reducing
ET-1- and PGF2α mediated cerebral vasoconstriction [126,130]. Vasoconstriction was notably reduced
and the vasorelaxant properties of the ETB1-R were restored. Furthermore, clear evidence exists,
that after aSAH, AT2-1-R are upregulated in experimental settings [132]. Here, an additive direct
antagonism on these receptors could reduce the sensitivity to an AT2-1-R-mediated vasocontraction to
angiotensin II, too [125,134]. LS possesses beneficial aspects on cerebral epileptogenicity, which could
be applied to the issue of reducing cortical spreading depression post aSAH [135–138]. Also, it is able
to restore post-ischemic cerebral autoregulation after hemorrhagic stroke [134].
Considering these neuroprotective effects of LS, the ethical question arises of whether the
philosophy of strictly discontinuing all antihypertensive agents after aSAH (except of new
administration of nimodipine), especially of LS, should stay state of the art. Next to beneficial
influences on DCVS after aSAH in rats as mentioned above, AT2-1-R antagonists clearly possess
beneficial effects after stroke regarding cerebral inflammation, the areal of infarction, cortical
spreading depression, cerebral microcirculation, and maintenance of pressure-dependent cerebral
vasoconstriction [23,64,71,105,127,134,139–141]. Appreciating these facts, a systemic LS administration
over and above the phase of DCVS, could be a promising approach in preventing these effects;
particularly because LS seems to not influence the global CBF in essential hypertonic patients, which
can be set equivalent to a needed-hypertonia after aSAH [142]. Here, LS could be an interesting
approach, because it increases global CBF despite lowering blood pressure [105], and is therefore
capable to reduce DCI [92]. Also, considering the positive vasomodulatory influences of LS, the question
arises whether after aSAH this medication should be established as secondary prophylaxis to avoid a
de-novo-aneurysm genesis, ergo, if aneurysms under LS are anyway arising [143].
4.1. Translational Aspects
Both abovementioned questions after aSAH are difficult to adapt to the affected patient group,
because common sense to date stays in discontinuing all antihypertensive agents after the initial
bleeding event. Also, it is vague to postulate that a LS effect persists after discharging this medication
on admission over the phase of DCVS for 14 days. Furthermore, the numbers of patients with LS
as standard antihypertonic medication receiving follow-up angiographys are too scarce to testify a
valid statement concerning case-control studies of aneurysm-growth/-development, as reviewed in
our own patient series in 2009–2015. Nevertheless, LS seems to be an underrated neuroprotective
drug, reducing cerebral inflammation and epileptogenicity, DCVS, and infarct size after ischemic
stroke. These results of preclinical ischemic stroke and aSAH research as well as clinical ischemic
stroke research could be applied in a prospective clinical setting of patients suffering aSAH. Also,
the question of a de-novo-aneurysm-genesis in further cranial control imaging could be addressed.
4.2. Synopsis and Forecast
LS, a selective AT2-1-R antagonist, was shown to directly antagonize and ameliorate the impaired
ETB1-R vasodilatory function. Given that in most clinical centers, antihypertensive agents are
discontinued during the period of DCVS, LS, although an antihypertensive drug, may have a role in
preventing delayed DCVS after aneurysm rupture given the effects shown in ischemia. Following
aSAH, immediate therapy with LS might antagonize the vasoconstrictive AT2-1-R without affecting the
dilatory AT2-2-R effect [132,144–151]. Furthermore, AT2 interestingly increases endothelin production
in non-cerebral vessels (an increased ET-1 concentration in rat aortas could be inhibited through LS
administration [140]) and thus indirectly enhances ET-1-mediated DCVS [123,152–156]. All these
aspects might suggest a crosstalk between both peptidergic systems extra- and intracranially [71,157].
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5. Conclusions
There is a promising effect on LS in the treatment of ischemic stroke both in preclinical and
clinical studies as well as in preclinical studies on aSAH. LS has shown to reduce ET-1-mediated
vasocontraction, cerebral inflammation, and restores vasodilatory function of the ETB1-R [26–28]. Thus,
LS may decrease the incidence of symptomatic vasospasm and improve functional outcome in aSAH
patients. Large, randomized, double-blinded clinical trials are necessary to determine its benefit
in aSAH.
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